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1. INTRODUCTION 
ANALYTICAL CHEMISTRY 
                    Analytical chemistry1,2 may be defined as the science and art of 
determining the composition of materials in terms of the elements of compound 
contained. By means of analytical techniques both qualitative and quantitative analysis 
can be done.  
Analytical chemistry is basically concerned with the determination of the 
chemical composition of matter however, identification of substance, the elucidation of 
its structure and quantitative analysis of its composition are the aspects covered by 
modern analytical techniques. 
Qualitative methods yield information about the identification of atomic or 
molecular species or functional groups in the sample.3 
Quantitative analysis establishes the relative amount of one more of the species 
or analyte in numerical terms. Qualitative information is required before a quantitative 
analysis is undertaken. 
 Steps involved in quantitative analysis: 3,4 
 Selection of method. 
 Chemical nature of sample  
 Elimination of possible interferences 
 Measurement of analyte  
 Calculation of results 
 Estimation of reliability of the results(validation) 
Classification of analytical methods:  
                           Analytical methods5 are often classified as being either classical or  
Instrumental methods.  
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Classical methods: 
                     The classical methods for separating and determining analyte still find use 
in many laboratories. For qualitative analysis the separated   components were then   
treated with reagents that yield products that could be recognized by their colors, their 
boiling or melting point the solubility in a series of solvents, their odour, optical 
activities and their refractive indexes. For quantitative analysis the amount of analyte 
was determined by gravimetric or titrimetric measurements the mass of the analyte or 
some compounds produced from the analyte was determined. In gravimetric 
measurements the mass of the analyte or some compounds produced from the analyte 
was determined. 
            In titrimetric procedures the volume or mass of a standard reagent required to 
react completely with analyte was measured.         
Instrumental methods:  
            In the instrumental methods6 the measurement of physical properties of analysis 
such as conductivity, electrode potential, light absorption, emission. Mass to charge 
ratio and fluorescence began to be used for quantitative analysis of a variety of 
inorganic, organic & biochemical analytes. 
           Chromatographic and electrophoretic techniques for the separation of 
components complex mixtures prior to their qualitative or quantitative determination.  
Analytical methods classification 3,7 
• Spectral methods  
• Chromatographic methods 
• Electrochemical methods 
• Miscellaneous methods  
• Hyphenated methods 
Spectral methods: 
• UV visible  spectroscopy  
• Atomic absorption spectroscopy  
• Fluorescence and phosphorescence spectroscopy  
• Infra red spectroscopy  
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• Nuclear magnetic resonance spectrometry 
• Electron spin resonance spectroscopy 
• Turbidometry 
• Nephlometry 
• Raman spectroscopy 
• X ray diffraction etc. 
Chromatographic methods  
• Thin layer chromatography 
• High performance liquid chromatography 
• Gas chromatography 
• Super critical fluid chromatography 
• Paper chromatography etc... 
Electrochemical methods  
• Conductometry  
• Potentiometry 
• Coulometry 
• Voltametry 
• Polarography 
• Amperometry 
• Elecrogravimetry 
• Paper electrophoresis 
• Colorimetry 
Miscellaneous methods 
• Thermal analysis  
• Mass spectrometry  
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Other Hyphenated methods:  
• Liquid chromatography-Mass spectroscopy,[LC-MS] 
• Liquid chromatography- Nuclear magnetic resonance spectroscopy,[LC-NMR] 
• Gas chromatography-Mass spectroscopy[GC-MS] 
• Mass spectrometry-Mass spectroscopy[MS-MS] 
 CHROMATOGRAPHY  
Chromatography8,9 is a technique used for the separation, purification and 
identification of the compounds of mixtures by their continuous distribution, between 
two phases. One is stationary phase and the other is mobile phase.  As a general rule, 
highly polar materials are best separated using partition chromatography, while very 
nonpolar materials are separated using adsorption chromatography. Between extremes, 
either process might be applicable.  
The Chromatographic technique was first invented by M.TSWETT in 1906.The 
term chromatography (Greek: - Khromatos – color and graphos –written) and its 
principles were first discovered by Mikhail Tswett. 
On the general progress of science, chromatography may be regarded as an 
analytical technique employed for the purification and separation of organic and 
inorganic substances. It is also found useful for the fractionation of complex mixture, 
separation of closely related compound such as isomers and in the isolation of unstable 
substances. 
In adsorption chromatography the adsorbent is usually kept constant, and the 
eluting solvent polarity is increased until elution is achieved. Some commonly used 
solvents in order of increasing polarity are: light petroleum solvents (hexane, heptanes, 
petroleum ether) < cyclohexane < toluene < dichloromethane < chloroform < ethyl 
ether < ethyl acetate < acetone < n-propanol < ethanol < water. 
Principles of Chromatographic Separation:10,11 
• Adsorption chromatography: a solid stationary phase and a liquid or gaseous 
mobile phase. 
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• Partition chromatography: a liquid stationary phase and a liquid or gaseous 
mobile phase. 
• Size exclusion chromatography: an inert gel which acts as a molecular sieve, 
and liquid mobile phase. 
• Ion exchange chromatography: a solid polymeric stationary phase containing 
replaceable ions. 
 
Adsorption chromatography: 
 In adsorption chromatography, mixture of compounds dissolved in the mobile 
phase, moves through a column of stationary phase, due to the affinity of the solute 
towards mobile or stationary phase, Solutes get separated.  Which compounds have 
lesser affinity elute first. In normal phase the mobile phase is non polar and the 
stationary phase is polar where in reverse phase the mobile phase is polar and the 
stationary phase is non polar.1 
Partition chromatography: 
 In partition chromatography the principle of separation is readily understood by 
considering the partitioning behavior of substance between two immiscible liquids. Few 
substances, when shaken with two immiscible liquids, partition take place completely in 
to one or other liquid.  Instead, most distribute themselves between the liquids such that 
the partition coefficient (the ratio of concentrations of the substance in each phase) is a 
constant value independent of the total amount, provided neither phase is saturated with 
the substance.27 
Mode of chromatographic operations:  
 There are three modes of chromatographic12,13 operation they are as follows: 
• Elution techniques 
- Isocratic method 
- Gradient method 
• Frontal techniques 
• Displacement techniques 
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Types of chromatography techniques: 
• Planar chromatography 
• Column chromatography 
TYPES OF LIQUID CHROMATOGRAPHY14,15 
• Liquid – Solid chromatography 
• Liquid – liquid chromatography 
• Gas liquid chromatography 
These three types are the basic types of chromatography and these are modified to 
different types of chromatography.  They are as follows; 
• Normal phase chromatography 
• Reverse phase chromatography 
• High performance liquid chromatography 
• Ion exchange chromatography 
• Size exclusion liquid chromatography 
• Super critical fluid chromatography 
• Chiral chromatography 
• Affinity chromatography 
Basic operations 
Liquid chromatography16,17 
1. Feed Injection: 
 The feed is added into the mobile phase and it is injected. The mobile phase 
flows through the column by the action of a pump. 
2. Separation in the column: 
 As the sample flows through the column, its different components will adsorb to 
the stationary phase to varying degrees.  Those with strong attraction to the support 
move more slowly than those with weak attraction.  This is how the components are 
separated. 
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3. Elution from the column: 
 After the sample is flushed or displaced from the stationary phase, the different 
components will elute from the column at different times.  The components with the 
least affinity from the stationary phase (the most weakly adsorbed) will elute first, 
While these with the greatest affinity from the stationary phase (the most strongly 
adsorbed) will elute last. 
4. Detection 
 The different components are collected as they emerge from the column. A 
detector analyses the emerging stream by measuring a property which is related to 
concentration and characteristic of chemical composition. For example the refractive 
index or ultra violet absorbance is measured. 
High performance liquid chromatography – [HPLC]  
High performance liquid chromatography (HPLC)18 is a form of column 
chromatography used frequently in biochemistry and analytical chemistry. The analyte 
is forced through a column (stationary phase) by a liquid (mobile phase) at high 
pressure, and the components get separated. 
Principles of HPLC: 
There are two types of principles which are as follows: 
• Isocratic elution 
• Gradient elution 
Isocratic HPLC: 
In isocratic HPLC the analyte is forced through column of the stationary phase 
by introducing a liquid at high pressure.  Use of pressure gives the components less 
time to diffuse within the column, leading to improved resolution in the resulting 
chromatogram. Solvents used include any miscible combination of water or various 
organic liquids (most common are methanol and acetonitrile).  Water may contain 
buffers or salts to assist in the separation of the analyte components or compounds such 
as trifluroacetic acid. 
Chapter : 1                                                                                              Introduction 
 
RVS College of Pharmaceutical Sciences, Coimbatore  Page 8 
 
Gradient HPLC: 
A further refinement to HPLC is to vary the mobile phase composition during 
the analysis, this is known as gradient elution. A normal gradient for reverse phase 
chromatography might start at 5% methanol and progress linearly to 50% methanol 
over 25 minutes, depending on how hydrophobic the analyte is. 
Different types of HPLC Techniques: 
• Normal phase chromatography. 
• Reverse phase chromatography. 
• Size exclusion chromatography. 
• Ion exchange chromatography. 
Reverse Phase Chromatography:  Reverse phase HPLC (RP-HPLC) consists of a non 
polar stationary phase and a polar mobile phase and was developed due to the 
increasing interest in large non-polar biomolecules One common stationary phase is a 
silica which has been treated with RMe2SiCl, where R is a straight chain alkyl group 
such as C18H37 or C8C17 etc.  The retention time is therefore longer for molecules which 
are more non-polar in nature, allowing polar molecules to elute more readily. Eluent 
time is increased by addition of less polar solvent. 
INSTRUMENTATION OF HPLC:6,9 
Fig No:1.1  FLOW SCHEME FOR HPLC 
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• Mobile phase 
• Pumps 
• Injector port 
• Stationary phase 
• Detector 
 MOBILE PHASE AND PUMPS: 
MOBILE PHASE:   
The mobile phase in RP-HPLC16,19 however, has a great influence on the 
retention of the solutes and the separation of component mixture. 
The primary constituents of reverse phase-mobile phase are water miscible 
solvents such as methanol, ethanol, acetonitrile, dioxin, and tetra hydro furan are added 
to adjust the polarity of the mobile phase.  The water should be high quality, either 
distilled or demineralised. The most widely used organic modifiers are methanol, 
acetonitrile and tetrahydrofuran. Methanol and acetonitrile have comparable polarities 
but the latter is an aprotic solvent. This factor may be important if hydrogen bonding 
plays a significant role in the separation. When inorganic salts and ionic surfactants are 
used, the mobile phase should be filtered before use, since these additivies frequently 
contain a significant amount of water insoluble contaminants that may damage the 
column.  Reverse phase mobile phase are generally noninflammable due to high water 
content. Degassing is quite important with reverse phase mobile phase. 
Selection of Mobile phase: 
Soluble in organic solvent: 
• Non-polar compounds 
- Normal phase chromatography 
- Reverse phase chromatography 
• Polar compounds 
- Non ionic 
 Reverse phase chromatography 
Ion forming 
 Reverse phase with pH control chromatography  
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Reverse phase ion paring chromatography 
- Basic 
 Normal phase chromatography 
 Reverse phase chromatography 
 Reverse phase with alkaline – eluent 
Soluble in water: 
* Non-ionic  – Reverse phase chromatography 
* Ion forming   – Reverse phase with pH control chromatography 
* Strong acid or bases – Reverse phase with ion pair chromatography  
* Inorganic cations – Ion exchange chromatography  
* Inorganic anion – Ion exchange chromatography 
* Organic acids – Ion exchange chromatography 
* Mono saccharides – Ion exchange chromatography  
     Reverse phase chromatography 
* Mono-Disaccharides– Ligand exchange chromatography 
     Reverse phase chromatography 
HPLC PUMPS: 
                 Pumps system in HPLC is constructed from the materials that are 
inert to all mobile phase or solvent system used. The most commonly used materials are 
glass, stainless steel, Teflon and sapphire.  The pumps are required to deliver a constant 
flow of mobile phase at pressure from 1 to 550 bar and 14.6 to 800 psi.  Pumps capable 
of generating pressure up to 8000 psi provides a wide range of flow rate of mobile 
phase typically from 0.01 to 10ml min-1. 
The solvent flow from the pump should be pulse less or should be dampened in 
order to remove pulses since the presence of pulses in the solvent flow may cause better 
result with some detectors. 
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HPLC INJECTION PORT AND COLUMN: 
INJECTION PORT FOR HPLC: 
• Samples are injected into the HPLC via an injection port. 
• The injection port of an HPLC commonly consists of an injection valve and the 
sample loop.  
• The sample is typically dissolved in the mobile phase before injection into the 
sample loop.  
• The sample is then drawn into a syringe and injected into the loop via the 
injection valve.  
• A rotation of the valve rotor closes the valve and opens the loop in order to 
inject the sample into the stream of the mobile phase. 
• Loop volumes can range between 10 µl to over 500 µl. In modern HPLC 
systems, the sample injection is typically automated.  
STATIONARY PHASE (COLUMN): 
• The stationary phase 20 in HPLC refers to the solid support contained within the 
column over which the mobile phase continuously flows. 
• The sample solution is injected into the stationary phase through the injector 
port.  
• As the sample solution flows with the mobile phase through the stationary 
phase, the components of that solution will migrate according to the non-
covalent interactions of the compounds with the stationary phase.  
• The chemical interactions of the stationary phase and the sample with the 
mobile phase, determines the degree of migration and separation of the 
components contained in the sample. 
• Some of the more common stationary phases include: Liquid-Liquid, Liquid-
Solid (Adsorption), Size Exclusion, Normal Phase, Reverse Phase, Ion 
Exchange, and Affinity.  
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• There are various columns that are secondary to the separating column or 
stationary phase. They are: Guard, Derivatizing, Capillary, Fast, and Preparatory 
Columns.  
COLUMN EFFICIENCY: 
• Column efficiency21 refers to the performance of the stationary phase to 
accomplish particular separations.  
• This entails how well the column is packed and its kinetic performance.  
• The efficiency of a column can be measured by several methods which may or 
may not be affected by chromatographic anomalies, such as "tailing" or 
appearance of a "front."  
• This is important because many chromatographic peaks do not appear in the 
preferred shape of normal Gaussian distribution.  
• For this reason efficiency can be an enigmatic value since manufacturers may 
use different methods in determining the efficiency of their columns. 
 DETECTORS: 
• The detector9 for an HPLC is the component that emits a response due to the 
eluting sample compound and subsequently signals a peak on the 
chromatogram.  
• It is positioned immediately posterior to the stationary phase in order to detect 
the compounds as they elute from the column.  
• The bandwidth and height of the peaks may usually be adjusted using the coarse 
and fine tuning controls, and the detection and sensitivity parameters may also 
be controlled (in most cases).  
• There are many types of detectors that can be used with HPLC. Some of the 
more common detectors include: Refractive Index (RI), Ultra-Violet (UV), 
Fluorescent, Radiochemical, Electrochemical, Near-Infra Red (Near-IR), Mass 
Spectroscopy (MS), Nuclear Magnetic Resonance (NMR), and Light Scattering 
(LS).  
• Ultra-Violet (UV) detectors measure the ability of a sample to absorb light. This 
can be accomplished at one or several wavelengths. 
Chapter : 1                                                                                              Introduction 
 
RVS College of Pharmaceutical Sciences, Coimbatore  Page 13 
 
• There are several ways of detecting when a substance has passed through the 
column. A common method which is easy to explain uses ultra-violet 
absorption. 
• Many organic compounds absorb UV light of various wavelengths. If you have 
a beam of UV light shining through the stream of liquid coming out of the 
column, and a UV detector on the opposite side of the stream, you can get a 
direct reading of how much of the light is absorbed. 
• The amount of light absorbed will depend on the amount of a particular 
compound that is passing through the beam at the time. 
 
 
                              
• One might wonder why the solvents used don't absorb UV light. They do! But 
different compounds absorb most strongly in different parts of the UV spectrum. 
•  Methanol, for example, absorbs at wavelengths below 205 nm, and water below 
190 nm. If you were using a methanol-water mixture as the solvent, you would 
therefore have to use a wavelength greater than 205 nm to avoid false readings 
from the solvent. 
Fixed wave length measures at one wavelength, usually 254 nm. 
Variable Wavelength measures at one wavelength at a time, but can detect over a wide 
range of wavelengths. 
Diode Array measures a spectrum of wavelengths simultaneously 
UV detectors have a sensitivity to approximately 10-8 or 10 -9 gm/ml. 
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• Calculation of column efficiency value:  
All the following methods use this formula that measures N, or number of theoretical 
plates:   
                                         
HPLC Methods of Analysis for Drugs14: 
         Most of the drugs in multicomponent dosage forms can be analyzed by HPLC 
method because of the several advantages like rapidity, specificity, accuracy, precision 
and ease of automation in this method. HPLC method eliminates tedious extraction and 
isolation procedures. Some of the advantages are:  
Â Speed (analysis can be accomplished in 20 minutes or less),  
Â Greater sensitivity (various detectors can be employed),  
Â Improved resolution (wide variety of stationary phases),  
Â Reusable columns (expensive columns but can be used for many analysis),  
Â Ideal for the substances of low volatility,  
Â Easy sample recovery, handling and maintenance,  
Â Instrumentation tends itself to automation and quantitation (less time and less 
labour),  
Â Precise and reproducible,  
Â Calculations are done by integrator itself,  
Â Suitable for preparative liquid chromatography on a much larger scale.  
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QUANTITATION 
Quantitation Methods in HPLC: 4, 17 
Peak height or peak area measurements only provide a response in terms of detector 
signal. This response must be related to the concentration or mass of the compound of 
interest. To accomplish this, some type of calibration must be performed.  
The four primary techniques for quantitation are  
1. Normalized peak area method 
2. External Standard method 
3. Internal Standard method 
4. Method of Standard addition 
 
1. Normalized peak area method: 
The area percent of any individual peak is referred to the normalized peak area. 
This technique is widely used to estimate the relative amounts of small impurities or 
degradation compounds in a purified material and in this method; the response factor 
for each component is identified. 
2. External Standard method: 
This method includes injection of both standard and unknown and the unknown 
is determined graphically from a calibration plot or numerically using response factors. 
A response factor (Rf) can be determined for each standard as follows. 
     Standard Area (Peak height) 
                             
                   Rf    =                   
       Standard Concentration    
            The external standard approach is preferred for most samples in HPLC that do 
not require extensive sample preparation. For good quantitation using external 
standards, the chromatographic conditions must remain constant during the separation 
of all standards and samples. External standards are often used to ensure that the total 
chromatographic system is performing properly and can provide reliable results. 
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3. Internal Standard method: 
              A widely used technique of quantitation involves the addition of an internal 
standard to compensate for various analytical errors. In this approach, a known 
compound of a fixed concentration is added to the known amount of samples to give 
separate peaks in the chromatograms to compensate for the losses of the compounds of 
interest during sample pretreatment steps. Any loss of the component of interest will be 
accompanied by the loss of an equivalent fraction of the internal standard. The accuracy 
of this approach obviously dependence on the structural equivalence of the compounds 
of interest and the internal standard.  
The requirements for an internal standard are:  
a. It must have a completely resolved peak with no interferences,  
b. It must elute close to the compound of interest,  
c. It must behave equivalent to the compound of interest for analysis like pretreatments, 
derivative formations, etc.  
d. It must be added at a concentration that will produce a peak area or peak height ratio 
of about unity with the compound,  
e. It must not be present in the original sample,  
f. It must be stable, unreactive with sample components, column packing and the 
mobile phase and  
g. It is desirable that this compound is commercially available in high purity.  
         The internal standard should be added to the sample prior to sample preparation 
procedure and homogenized with it. To be able to recalculate the concentration of a 
sample component in the original sample, we have to demonstrate first the response 
factor. The response factor (RF) is the ratio of peak areas of sample component (Ax) 
and the internal standard (AISTD) obtained by injecting the same quantity. It can be 
calculated by using the formula,  
                                         
STDIA
AxRf
..
=  
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         On the basis of the response factor and strength of the internal standard (NISTD), 
the amount of the analyte in the original sample can be calculated using the formula,    
                                                                          STD
STDF
S xN
AR
AX .1
1.
=  
          The calculations described above can be used after proving the linearity of the 
calibration curve for the internal standard and the analytical reference standard of the 
compound of interest. When more than one component is to be analyzed from the 
sample, the response factor of each component should be determined in the calculations 
using similar formula.  
4. Method of Standard addition: 
The method of standard addition can be used to provide a calibration plot for 
quantitative analysis. It is most often used in trace analysis. An important aspect of the 
method of standard addition is that the response prior to spiking additional analytes 
should be high enough to provide a reasonable S/N ratio (>10), otherwise the result will 
have poor precision. 
ANALYTICAL METHOD DEVELOPMENT22,23 
                 Selecting an accurate assay procedure for each ingredient present in 
pharmaceutical dosage forms, either individually or complex dosage formulation 
containing several therapeutically and chemically compatible drugs with very similar 
chemical nature is a monumental undertaking. 
Separation, identification and estimation of each ingredient in such complex 
formulation are a challenging task.  The presence of excipients, additives and 
decomposition products further complicates the analysis. Therefore analytical 
development is done for new drug where no methods are available. Or, alternate 
method development for existing (non pharmacopoeia) products to reduce cost and time 
of analysis. 
Method development is done for 
1. New products 
2. Existing products 
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Methods are developed for new products when no official methods are 
available. Alternate methods for existing (non-pharmacopoeia) products are developed 
to reduce the cost and time for better precision and ruggedness. 
STEPS TO BE FOLLOWED IN METHOD DEVELOPMENT 
Method development22 starts with the documentation of the developed studies. 
All data related to these studies must be established and they must be recorded in 
laboratory notebook or an electronic data base. 
1. Standard Analyte Characterization:- 
¾ Collection of information about the analyte or drug should be collected starting 
from the structure, physical, chemical properties toxicity, purity, hygroscopic 
nature, solubility and stability. 
¾ Reference standard for the sample should be obtained. In case of multiple 
components for the analysis to be analyzed in the sample, number of 
components should be noted, data is assembled and the availability of standards 
for each one is determined. 
¾ Proper storage are set for the reference standards (refrigerators, dessicator, 
freezer). 
¾ A suitable method for the sample is considered. 
2. Method Requirements:- 
The aim or requirement of the analytical method that need to be developed all 
considered and the analytical figures of merit are defined. The required detection limits, 
selectivity, linearity, range, accuracy and precision are defined. 
3. Literature Search and prior Methodology:- 
The literature for all types of information related to the analyte surveyed. 
Literature is done for synthesis, physical, chemical properties, solubility and related 
analytical method. Information can be obtained from official standard books such as 
USP/NF, AOAC standard books, periodicals, chemical manufacturers along with 
chemical abstract services and computer data banks. 
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4. Choosing of Method:- 
¾ Adaptation is more efficient than “reinventing the wheel”. If any of the 
reported methods from the literature are adaptable to the current laboratory 
setting and future needs, it is determined. 
¾ From the various source a methodology is adopted. The methods are 
modified. 
¾ If there are no reported details for the drug or the chemical then the drugs 
are investigated and are worked out. 
5. Instrumental Setup and Initial Studies:- 
¾ By using the data made for the analyte a suitable instrument method is 
selected. The instrument is set up by using standard operation procedure.  
¾ Analyte reference standard is prepared in suitable concentration by using 
various combination of solvent system. It is important to start with reference 
standard substance rather then complex sample components. 
¾ The analysis is made for the various conditions described in the existing 
literature. 
6. Optimization: 
During optimization one parameter is changed at a time, and set of conditions 
are isolated, rather than using a trial and error approach. Work has been done from an 
organized methodological plan, and every step is documented (in a lab note book) in 
case of dead ends. 
7. Documentation of analytical figures: 
 The originally determined analytical figures of merit, Limit of quantitation 
[LOQ] and Limit of the detection [LOD],  linearity, time per analysis cost, sample 
preparation etc are documented. 
8. Evaluation of Method Development with actual Sample: 
The sample solution should lead to unequivocal, absolute identification of the 
analyte peak of interest apart from all the other matrix components. 
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9. Determination of Percent Recovery of Actual Sample and Demonstration of      
Quantitative Sample Analysis: 
Percent recovery for the standard analyte into a sample matrix that is shown to 
contain no analyte is determined. Reproducibility of recovery from sample to sample 
and whether the recovery has been optimized has been shown. It is not necessary to 
obtain 100% recovery as long as the results are reproducible and known with high 
degree certainty. 
The validity of analytical method can be verified only by laboratory studies. 
Therefore documentation of the successful completion of the studies is the basic 
requirement for determining whether a method is suitable for its intended applications. 
Validation is an approach to form a basis for written procedures for production 
and process control which are designed to assure that the drug products have the 
identity strength, quality, and purity they purport or are represented to possess. 
VALIDATION OF ANALYTICAL METHOD DEVELOPMENT 
Introduction: 
       Analytical method validation24,25 is the process of demonstrating that analytical 
procedures are suitable for their intended use and provide accurate test results that 
evaluate a product against its defined specification and quality attributes. 
           It is process involving confirmation or establishing by laboratory studies the 
method / procedure/ system/ analyte gives accurate and reproducible result for intended 
application in a proven and established range. That performance characteristic of the 
method (accuracy, precession,  sensitivity, ruggedness etc). 
Definitions of validation: 
World health organization (WHO): Action of providing that any procedure, process, 
equipment, material activity, or system actually reads to the expected results.  
Food and drug administration (FDA US): Establishing documentation evidence, 
which provides a high degree of assurance that specific process, will consistently 
produce a product meeting its predetermined specification and quality attributes. 
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European committee(EC): action of providing in accordance with the principle of 
good manufacturing practice, that any procedure process equipment material, activity or 
system actually read to the expected result. 
Types of validation:26 
Prospective Validation: At least three successive production size (US Via) batches, all 
batches made tested and report approved before distribution facilities and equipment 
qualified. 
Concurrent Validation: Generation of validation data concurrent or simultaneously 
with normal production schedules used in exceptional cases (low volume products); 
interim reports required. 
Retrospective Validation: This is establishing documented evidence that the process is 
performed satisfactorily and consistently over time, based on review and analysis of 
historical data. The source of such data is production and QA/QC records. The issues to 
be addressed here are charged to equipment, process, specification and other relevant 
changes in the past. 
1.9.1 VALIDATION OF ANALYTICAL PROCEDURES 19,27 
Definitions, Methodology and Acceptance Criteria: 
Different Types of Validation characteristics: 
 Precision           
 Accuracy 
 Specificity and Selectivity 
 Linearity and Range 
 Solution stability 
 Limit of Detection (LOD) 
 Limit of Quantification (LOQ) 
 Robustness 
 Ruggedness. 
 System Suitability 
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Generalized validation process for an HPLC assay method:  
 Validation11 is the process of collecting documented evidence that the method 
performs according to its intended purpose.  The validation process has been 
described as follows: 
Table No: 1 schematic diagram of method development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
START
Approved protocol 
    1. Scope. 
2. Responsibilities. 
3. Define reagents and working solutions. 
Determine method specificity 
1. Degrade samples. 2. On‐line analysis using 
Diode Array UV.
Solution stability 
Controlled ambient conditions‐up to 7 
days 
1. Standards and Samples. 
Linearity 
1. LOD, LOQ. 
2. Linearity. 
3. Accuracy. 
Precision 
1. Injection and Analyst Repeatability. 
2. Intermediate Precision. 
3. Reproducibility. 
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1. Accuracy  
             Accuracy2 is the closeness of test results obtained by that method to the true 
value. The accuracy of an analytical method should be established across its range. 
There are several methods that can be used for determining accuracy. The most 
common include 
          Analyze a sample of known concentration and compare the measurement to the 
true value. In this case, method accuracy is the agreement between the difference in the 
measured analyte concentration and the known amount of analyte added. That is the 
accuracy or % recovered is calculated as:  
                                     Cm × 100     
         Ct 
            Where   Cm  is the measured concentration  
                           Ct  is the theoretical concentration.            
Accuracy has also been reported as a sample is analyzed and the measured value should 
ideally be identical to the true value. Accuracy is represented and determined by 
recovery experiments. The usual range is being 10% above or below the expected range 
of claim. The % recovery was calculated using the formula, 
                                                                   (a + b) -a 
                      
 Percentage Recovery =                        
              b×100 
    Where, 
                    a – Amount of drug present in sample 
 b – Amount of standard added to the sample 
Evaluation and Final Report 
1. Process and Evaluate Results and Data. 
2. Compare Results Vs Acceptance Criteria. 
FINISHED
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ICH states that accuracy should be assessed using a maximum 9 determination over a 
minimum of 3 concentration levels covering the specified range (eg. 3 concentration /3 
replicates each of the total analytical procedure).   
Acceptance Criteria: 
¾   For an assay method, mean recovery will be 100%± 2% at each 
concentration over the range of 80-120% of the target concentration. 
¾ For an impurity method, mean recovery will be 0.1% 
absolute of the theoretical concentration or 10% relative, whichever is 
greater for impurities in the range of 0.1-2.5 % (V/W). 
2. Precision:   
             Precision25,28 of an analytical procedure expressed the closeness of agreement       
(degree of scatter) between a series of measurement obtained from multiple samplings 
of the same homogeneous sample under prescribed condition. 
         The precision of test method is usually expressed as the standard deviation or 
relative standard deviation of a series of measurements. Precision may be considered at 
three levels: Repeatability, Intermediate Precision and Reproducibility. 
System precision:  
        A System precision was evaluated by measuring the peak response of drug for six 
replicate injection of the standard solution preparation as per the proposed method. 
Method precision:  
         The method precision was determined by preparing the sample of a single batch of 
the drug for tablet formulation six times and analysed as per the propsed method. 
Acceptance Criteria: 
¾ Percentage Relative standard deviation (%RSD)  NMT 1 % (Instrument 
precision) 
¾ (%RSD)  NMT -2% (Intra- assay precision) 
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3. Specificity: Specificity28 is the ability to assess unequivocally the analyte in the 
presence of components which may be expected to be present. Typically these might 
include impurities, degradants, matrix, etc. Specificity shall be demonstrated by 
performing Placebo / blank interference and forced degradation studies. 
a. Blank interference:  
  Blank solution is prepared and analysed as per test method. 
b. Placebo interference (In case of Drug products):  
 The placebo solution equivalent to the test concentration is also prepared and 
analysed as per the test method. 
4. Forced Degradation studies:  
           The sample is degraded forcefully under the various stress conditions like 
Light, heat, humidity, acid / base / water hydrolysis and oxidation to ensure the 
degradation ranging 1 % to 20 %. 
         a) Light: The Drug product, drug substance and placebo are exposed to UV light 
for about 200 watt hours / square meter and the overall illumination not less than 1.2 
million Lax hours  for visible light. The sample and placebo solution are prepared as per 
test method and analyzed. 
    b) Humidity: The Drug product, drug substance and placebo are exposed for 
about 80% RH at about 25°C for about one week. Prepare the sample and placebo 
solution as per test method and analyzed. 
         c) Heat: The Drug product, drug substance and placebo are exposed at 105°C for 
about 12 hours (For substance having low melting point below 10°C of its melting 
point). The sample and placebo solution are prepared as per test method and analyzed. 
         d)  Acid / Base: The 0.1N acid or base solution of the drug refluxes the sample 
and placebo with 50 ml of acid / base solution for about 1 hour at 60°C. Neutralize the 
solution and dissolve the contents in diluents as per test method. Change the strength of 
acid and base or reflux time to ensure the desired degradation. 
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         e) Oxidation: The sample was refluxed for 12 hour at 60°C with 1 % H2O2 or 
suitable oxidant and dissolved the contents in diluents as per test method. The reflux 
time was changed so as to ensure the desired degradation. 
         f) Water: The sample / placebo was refluxed with 100 ml of purified water for 12 
hour at 60°C. Dissolve the contents in diluents as per test method. Change the reflux 
time so as to ensure the desired degradation. 
Note: Based on the physic-chemical properties and literature stress conditions can be 
decided. 
Acceptance Criteria: 
¾ Placebo / Blank should not elute at the retention time of analyte peak and 
known impurity peak. 
¾ Peak purity of analyte peak should be confirmed. 
¾ Degradation of active analyte peak should be from 1% to 20%.23 
 
5. Limit of Detection:  
          The limit of detection4 is the lowest concentration of analyte in a sample that can 
be detected but not necessarily determined in quantitatively using a specific method 
under the required experimental conditions. Such a limit is expressed in terms of 
concentration of analyte in the sample. 
Following are different approaches: 
1. Visual Evaluation Method: 
           The sample solutions have to be prepared with known lowest concentrations of 
analyte and establish the minimum concentration at which the analyte can be reliably 
detected by analyzing as per test method. 
a. Based on Signal to Noise Ratio Method: 
                  The LOD can be expressed as a concentration at specified signal-to-noise 
(S/N) ratio obtained from samples spiked with analyte. A signal-to-noise(S/N) ratio 
between 3:1 and 2:1 is generally considered acceptable. 
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b. Based on the standard Deviation of the Response and the Slope: 
¾ The blank solution has to be prepared as per test method and inject six 
times into the chromatographic system. 
¾ Similarly the linearity solution staring from lowest possible 
concentration of analyte to 150 % (or as per protocol) of target 
concentration have to be prepared to establish the linearity curve. 
 The detection limit (DL) may be expressed as : 
                        3.3 X Standard deviation of the response of the blank (σ) 
       LOD   =   
                                                                          Slope 
                S= slope of the calibration curve of the analyte. 
The slope shall be estimated from the calibration curve of the analyte. 
6. Limit Of Quantitation: 
              The limit of quantitation4 is the lowest concentration of the analyte in a sample 
that can be determined with acceptable precision and accuracy under the stated 
experimental conditions quantitation limit is expressed as the concentration of analyte 
(eg. Percentage, parts per million) in the sample. 
Following are different approaches:  
a.  Visual Evaluation Method: 
              The sample solutions with known lowest possible concentrations of analyte 
and establish the minimum concentration at which the analyte can be reliably 
quantified by analyzing as per test method. 
b. Based on signal to noise ratio method : 
              The LOQ can be expressed as a concentration at specified signal-to-noise 
ratio obtained from samples spiked with analyte. A signal-to-noise ratio of 10:1 is 
generally considered acceptable. The ratio recognized by the ICH (1996) is a general 
rule. It has been stated that “the determination of LOQ is a compromise between the 
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concentration and the required precision and accuracy. That is, as the LOQ 
concentration level decreases, the precision increases. 
c. Based on the standard Deviation of the Response and the Slope: 
 The blank solution as per test method and inject six times into the chromatographic 
system. Similarly the linearity solution staring from lowest possible concentration of 
analyte to 150% (or as per protocol) of target concentration and establish the linearity 
curve. 
The limit of quantitation (LOQ) may be expressed as : 
                                 10 X Standard deviation of the response of the blank(σ) 
                   LOQ =   
                                                                   Slope 
 The slope shall be estimated from the calibration curve of the analyte. 
Acceptance Criteria: 
¾ In Pharmaceutical application, the LOQ is typically set at minimum 0.05% 
for active pharmaceutical ingredients. 
¾ LOQ is defined as the lowest concentration providing a RSD of 5%. 
¾ LOQ should be at least 10% of the minimum effective concentration for 
clinical applications. 
¾ Signal -to- noise ratio is 10:1. 
7. Linearity and range:  
        Linearity: Linearity is the ability of the method to obtain test results that are 
directly proportional to the analyte concentration within a given range. 
        Range: Range of analytical procedure is the interval between the upper and lower 
concentration of analyte in the sample (including concentrations) for which it has been 
demonstrated that the analytical procedure has a sutable level of precision, accuracy, 
and linearity. 
Measurement: A range of standards should be prepared containing at least 5 different 
concentration of analyte which are approximately evenly spaced and span 50-150% of 
the label claim. 
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             At least 6 replicates per concentration to be studied.  Plot a graph of 
concentration (on X-axis) Vs mean response (on Y-axis) calculates the regression 
equation. 
           Y – Intercept and correlation coefficient.  Plot another graph of concentration (on 
X-axis) Vs response ratio (replicate response divided by concentration on Y-axis). 
The range of the method is validated by verifying that the analytical method 
provides acceptable precision, accuracy, and linearity when applied to sample 
containing analyte at the extreme of the range as well as within the range. 
Acceptance criteria: 
 Coefficient of correlation should be NLT 0.99. 
8. Ruggedness: 
           Degree of reproducibility of test results obtained by the analysis of the same 
sample under a verity of conditions, such as different laboratories, different analysts, 
different instruments etc. 
         Normally  expressed as the lack of influence on test results of operational and 
environmental variable of the analytical method. 
        Ruggedness is a measure of reproducibility of test results under the variation in 
condition normally expected from laboratory to laboratory and from analyst to analyst  
 The following are the typical method parameters need to tested during method       
      validation:  
¾  Analyst-to-Analyst variability. 
¾  Column-to-Column variability. 
¾  System-to-System variability. 
¾  Different days. 
¾  Different Laboratories. 
¾  Stability of Solutions and mobile phase.  ( At least for 48 hours ) 
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9. Robustness: 
            Robustness of an analytical method is a measure of its capacity ti remain un 
affectedly small but deliberate variations  in method parameters and provides an 
indication of its reliability during normal usage. 
                 For example a chromatographic method, the typical method parameters need 
to change deliberately and verify during method validation:  
    Flow rate   : (+/- 0.2ml/minutes). 
    Mobile phase composition         :       (+/- 10% of organic phase). 
    Column oven temperature  : (+/- 5°C). 
     PH of buffer in mobile phase : (+/- 0.2 units). 
     Filter suitability   : (At least two filters). 
For Variations:  
 1. System suitability should meet the acceptance criteria as per test method.  
 2. If system suitability doesn’t meet, the variation range is narrowed and carried out 
the experiment again to meet system suitability. 
 
10. SYSTEM SUITABILITY TESTING 
System suitability testing14 is an integral part of many analytical procedures. 
The tests are based on the concept that the equipment, electronics analytical operation 
and samples to be analyzed constitute an integral system that can be evaluated as such. 
System suitability test parameters to be established for a particular procedure depend on 
the type of procedure being validated. 
System Suitability Parameters 
¾ Tailing factor 
¾ Theoretical plate number 
¾ Theoretical plate per meter 
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¾ Resolution factor 
¾ Capacity factor  
¾ Precision / Injection repeatability 
¾ Relative retention 
a. Tailing factor: 
Asymmetry factor24 of a peak was calculated from the following expression: 
      Peak tailing factor = 
A2
BA +
 
A – Left half of the peak at 5% peak height when the peak is bisected with a 
perpendicular line dropped from the maximum of peak interest. 
B – Right half of the peak at 5% peak height when the peak is bisected with a 
perpendicular line dropped from the maximum of peak interest. 
b. Theoretical plate number (N):24 
The assessment of performance of column efficiency of a column is in terms of 
number of theoretical plate  
An equation shown below: 
                                 N = 5.54[t/wh/2] 
Where, 
t    = Retention time 
     Wh/2 = width of peak at half weight 
Theoretical plate number is a measure of column efficiency. i.e. how many 
peaks can be located per unit run time of the chromatogram ,‘H’ or ‘HETP’, the 
height equivalent to the theoretical plate, measures the column efficiency per unit 
length of the column. Parameters which can affect ‘N’ or ‘H’ include peak position 
particle size in column, flow rate of mobile phase and molecular weight of the 
analyte. 
c. Capacity factor:22 
It reflects the location of peak of interest with respect to the void volume i.e. 
elution time of the unretained compound. 
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                                        K1= (tr-to)-to      
 [tr – retention of analyte, to – retention of void or unretained component.] 
Methods used for the examination of pharmaceutical material may be broadly 
classified as; 
d. Resolution: 27 
R = 2 [(t2-t1)/ w2+w1] 
t2, t1 are the retention time 
w2, w1 are the peak width at base line respectively. 
Resolution is to measure how well the resulting two peaks are separated. For 
reliable quantitation well separated peaks are essential for quantitation. This is a very 
useful parameter if potential interference peak may be of concern. The closest eluting 
peak to the analyte should be selected. 
 
System Suitability Parameters and Recommendations (ICH Guidelines) 
Parameter                                                             Recommendation  
Capacity Factor (k’)                   the peak should be well-resolved from other peaks and    
                                                     the void volume, generally k’>2.0  
Repeatability                              RSD </= 1% for N >/= 5 is desirable.  
Relative retention                       not essential as long as the resolution is stated.  
 
Resolution (Rs)                           Rs of > 2 between the peak of interest and the closest  
                                                    eluting potential interferent (impurity, excipients,   
                                                    degradation product, internal standard, etc). 
Tailing Factor (T)                        T of </= 2  
Theoretical Plates (N)                 In general should be > 2000  
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Class A:   Test designed to establish identity, whether of bulk drug substances or   
                 particular ingredient in a finished dosage form. 
Class B:  Method designed to detect and quantitative impurities in a bulk drug 
substance or finished dosage form. 
Class C:  Methods used to determine quantitatively the concentration of a bulk drug 
substance or of a major ingredient in a finished dosage form. 
Class D:  Methods used to assess the characteristics of finished dosage forms such as 
dissolution profile and content uniformity. 
Table No: 2 Characteristics that should be considered for different Type of 
analytical procedure:- 
S.No Parameters Class A 
Class B 
Class C Class D Quantitative 
test 
Limit 
test 
1. Accuracy - Yes - Yes Yes 
2. Precision - Yes - Yes Yes 
3. Robustness Yes Yes Yes Yes Yes 
4. Linearity and 
Range 
- Yes - Yes Yes 
5. Selectivity Yes Yes Yes Yes Yes 
6. LOD Yes Yes Yes - - 
7. LOQ - Yes - - - 
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                                        2. LITERATURE REVIEW  
1. Anindita Behera  et al 29., (2011)  have down  Development and validation of 
Spectrophotometric method for determination of Emtricitabine and Tenofovir 
Disoproxil Fumarate in Bulk and Tablet dosage form. Three simple 
Spectrophotometric methods have been developed for simultaneous estimation of 
Emtricitabine and Tenofovir Disoproxil Fumarate from tablet dosage form. Method A 
is Least Square method, involves the measurement of Emtricitabine and Tenofovir 
Disoproxil Fumarate at their λmax at 281.0 nm and 260.5nm respectively. Method B 
is First order derivative spectroscopy, wavelength selected for quantitation were 
234.5nm for Emtricitabine (zero cross for Tenofovir Disoproxil Fumarate ) and 
281.0nm for Tenofovir Disoproxil Fumarate (zero cross for Emtricitabine). Method C 
is Area under Curve method, AUC in the range of 278.0- 283.0nm (for Emtricitabine) 
and 258.0- 262.0nm (for Tenofovir Disoproxil Fumarate) were selected for the 
analysis. The linearity lies between 5-25μg/ml and 10–50μg/ml for Emtricitabine and 
Tenofovir Disoproxil Fumarate respectively 
 for method A, B and C. 
 
2. Rajesh Sharma1 et al 30., (2009) have developed   RP- HPLC Method for 
Simultaneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumerate in a 
Tablet Dosage Form. The estimation was carried out on Luna C18 (25cm x 4.60 mm, 
particle size 5μm) column with a mixture of acetonitrile: potassium dihydrogen 
phosphate buffer (pH 3.0 ± 0.05 adjusted with orthophosphoric acid): triethylamine in 
the ratio of 70:30:0.5(v/v) as mobile phase. UV detection was performed at 260 nm. 
The method was validated for linearity, accuracy, precision, specificity and sensitivity 
as per ICH norms. The developed and validated method was successfully used for the 
quantitative analysis of commercially available dosage form. The retention time was 
1.78 and 2.27 min. for emtricitabine and tenofovir disoproxil fumarate respectively 
and total run time was 4 min. at a flow rate of 1.5 mL min-1. The calibration curve 
was linear over the concentration range of 5-50 μg mL-1 for emtricitabine and 5-50 μg 
mL-1 for tenofovir disoproxil fumarate. The LOD and LOQ values were found to be 
0.015 and 0.045 μg mL-1 for emtricitabine and 0.039 and 0.117 μg mL for tenofovir 
disoproxil fumarate respectively. The high percentage of recovery and low percentage 
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coefficient of variance confirm the suitability of the method for the simultaneous 
estimation of emtricitabine and tenofovir disoproxil fumarate in tablet dosage form 
 
3. Shirkhedkar Atul A et al31., (2009)  have work down   application of uv- 
spectrophotometric methods  for estimation of  Tenofovir  disoproxil fumarate in 
tablets. Tenofovir  disoproxil fumarate was estimated at 260 nm in 0.1N HCl.  It 
showed amplitude at 273 nm,  In both the methods linearity was found to be in the 
range of 5 - 40 μg/ml.  UV- Spectrophotometric method (Y=0.02586 X+0.0083; 
r2=0.9999)  and   for first order derivative spectrophotometric method (Y=0.00132 
X+0.00035; r2=0.9995), respectively. These methods were tested and validated for 
various parameters according to USP guidelines. The quantitation limits were  found 
to be 1.546 and 1.986μg/ml, for both the methods. 
 
 
4.  Manish Yadav et al 32., (2010) have done Selective Determination of Antiretroviral 
Agents Tenofovir, Emtricitabine, and Lamivudine in Human Plasma by a LC-MS-MS 
Method for a Bioequivalence Study in Healthy Indian Subjects. The chromatographic 
separation is achieved in a run-time of 3.0 min on an ACE 5 CN column under 
isocratic conditions. The mobile phase consisted of 0.5% formic acid in water and 
acetonitrile (55:45, v/v). The protonated precursor product ion transitions for TFV, 
FTC, 3TC, and internal standard were monitored on a triple quadrupole mass 
spectrometer operating in the multiple reaction monitoring (MRM) and positive ion 
mode. A linear dynamic range of 4.0-802 ng/mL, 15.0-3006 ng/mL, and 20.1-4023 
ng/mL is established for TFV, FTC, and 3TC, respectively, using 0.2 mL plasma 
sample. The method is fully validated for its sensitivity, selectivity, accuracy and 
precision, ion suppression, matrix effect, recovery, stability, and dilution integrity. It 
is successfully applied to a bioequivalence study of [300(TFV) + 200(FTC) + 
300(3TC)] mg tablet formulation in 43 healthy human subjects under fasting 
conditions. 
 
 
5. Narendra Devanaboyina et al.,33 work down in  hplc method development and 
validation for simultaneous estimation of tenofovir and emtricitabine in combined 
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pharmacetuical dosge form. Chromatography was carried out by using Chromosil C-
18 column internal diameter with a mixture of methanol, acetonitrile and TEA in the 
ratio of  46:50:04 (v/v/v) as mobile phase.  Determination of the different analytical  
parameters such as  linearity, precision, accuracy, and specificity, limit of detection 
(LOD) and limit of quantification (LOQ) was done. The calibration curve was found 
to be linear for each analyte in the desired concentration range. The  % recovery was 
found to be 99.59 and  99.61 for Tenofovir and Emtricitabine respectively.  The 
proposed method is highly sensitive, precise and accurate, which was evident from the 
LOD value of 0.05 and 0.02 ppm for Tenofovir and Emtricitabine respectively and 
hence the present method can be applied successfully for the quantification of active 
pharmaceutical ingredient (API) content in the combined formulations of Tenofovir 
and Emtricitabine. 
 
 
6.   P.Chandra et al.,34 have done application of high-performance thin-layer 
chromatographic method for the simultaneous determination of lamivudine and 
tenofovir disoproxil fumarate in pharmaceutical dosage form  The separation was 
carried out on Merck HPTLC aluminum plates of silica gel 60 F254, with 250 µm 
thickness using chloroform: methanol: toluene (8: 2: 2, v/v/v) as mobile phase. 
HPTLC separation of the two drugs followed by densitometric measurement was 
carried out in the absorbance mode at 265 nm. The drugs were satisfactorily resolved 
with Rf values of 0.27± 0.01 and 0.51± 0.01 for LAM and TDF, respectively. The 
linear regression analysis data for the calibration plots showed good linear relationship 
with r2=0.9999 and 0.9996 for Lamivudine and Tenofovir disoproxil fumerate 
respectively in the concentration range of 60-210 ng spot1 for each drug.  
 
7.  R.Sharma etal35.,(2010)  developed a  Simultaneous spectrophotometric estimation of 
tenofovir disoproxil fumarate and lamivudine in three component tablet formulation 
containing  efavirenz. The absorption maxima of the drugs were found to be 247, 259 
and 272 nm, respectively for efavirenz, tenofovir disoproxil fumarate and lamivudine in 
methanol : water (50:50) solvent system. Efavirenz, tenofovir disoproxil fumarate and 
lamivudine obeyed Beer’s law in the concentration range of 10-60, 5-30, and μg/ml, 
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respectively. Results of analysis for all the three methods were analysed and validated 
for various parameters according to ICH guidelines.  
 
 
8.  Ramesh.J  et al 36 ., have done   Simultaneous Estimation of Lamivudine and Tenofovir 
Disoproxil  Fumerate in Pure and in Tablet Formulation by First Derivative 
Spectrophotometric Method. The solutions of standard and sample were prepared in 
methanol. Quantitative determination of the drugs was performed at 261 nm and at 249 
nm for Lamivudine and Tenofovir disoproxil fumerate, respectively. Proposed method 
was evaluated for the different validation parameters. The specificity test showed that 
there was no interference from excipients commonly found in the commercial 
pharmaceutical formulations at the analytical wavelengths of Lamivudine and 
Tenofovir disoproxil fumerate. Quantification was achieved over the concentration 
range of 5 – 30 μg/ ml for Lamivudine and for Tenofovir disoproxil fumerate 
respectively. The correlation coefficient of Lamivudine and Tenofovir disoproxil 
fumerate was found to be 0.9991 and 0.9992 respectively.The mean recovery was 
100.21and 98.96 % for Lamivudine and Tenofovir disoproxil fumerate, respectively. 
This method is simple, precise, and sensitive and applicable for the simultaneous 
determination of Lamivudine and Tenofovir disoproxil fumerate in pure powder and 
formulation. 
 
9   Malipatil S M et al 37., (2009) have reported the determination of Tenofovir             
Disoproxil Fumarate by a sensitive simple isocratic RP-HPLC method using Luna C18 
column, mobile phase is 0.1%formic acid: acetonitrile (50:50), flow rate is 0.8ml/min 
with UV detection is 305nm. 
 
10.     S. Sentenac,  et al 38., (2003) have done the Sensitive determination of   tenofovir in 
human plasma samples using reversed-phase liquid chromatography. A solid–liquid 
extraction procedure was coupled with a reversed-phase HPLC system. The system 
requires a mobile phase containing Na2HPO4 buffer, tetrabutylammonium hydrogen 
sulfate and acetonitrile for different elution through a C18 column with UV detection. 
The method proved to be accurate, precise and linear between 10 and 4000 ng/ml. 
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11. Alain Pruvost et al39., have done  Pilot Pharmacokinetic Study of Human 
Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate 
(TDF) Investigation of Systemic and Intracellular Interactions between TDF and 
Abacavir, Lamivudine, or Lopinavir-Ritonavir   Liquid chromatography-tandem mass 
spectrometry was used to measure NRTIs and NRTI-TPs. Statistical analyses were 
performed on pharmacokinetic parameters: the area under the concentration-time curve 
from 0 to 4 h ,  the maximum concentration of the drug (Cmax), and the residual 
concentration of the drug at the end of the dosing interval (Ctrough) for plasma and the 
AUC0-4 and Ctrough for  intracellular data. 
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Physical Properties of   Lamivudine 
 
Color                           :   White crystalline solid 
Melting Point              :    160-162oC   
State                            :     Tablet 
Solubility                     :      Aqueous solubility  - 70mg/ml at 200 c  
                                              Highly Soluble in 0.01 N Hcl                           
                                
                               Pharmacological  Properties 
 
Dosage Form                      :         Tablet 
Route of administration    :         Oral 
 
Pharmacology   :  Lamivudine was rapidly absorbed after oral administration in HIV-infected 
patients. Absolute bioavailability in adults is 86% ± 16% for the tablet and 87% ± 13% for the 
oral solution 
Mechanism of Action  : Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 
2) of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B. It is 
phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit 
the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA 
synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the 
formation of the 5' to 3'phospho di ester linkage essential for DNA chain elongation, and 
therefore, the viral DNA growth is terminated. 
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 Solubility                  :       Slightly soluble in water, soluble in methanol, sparingly  
                                           soluble in acetone,  very slightly soluble in 
                                           methylene chloride.                                                                        
                                 
                                  Pharmacological  Properties 
Dosage Form                      :         Tablet 
Route of administration    :         Oral 
 
Pharmacology  : Tenofovir exhibits longer serum (7 hours) and intracellular (>60 hours) half – 
lives than those of nucleoside analogues, which supports a flexible once – daily administration 
schedule. The pharmacokinetics of Tenofovir are dose – proportional and similar in healthy 
volunteers and HIV – infected individuals. The oral bioavailability of Tenofovir is enhanced by 
administration with a high – fat meal, but is similar at steady state when administered with or 
without a typical meal.  
Mechanism of Action :   Before phosphorylation, tenofovir disoproxil fumarate is converted to 
tenofovir in the intestinal lumen and plasma by di ester hydrolysis. Tenofovir is then internalized 
into cells, possibly by endocytosis, and subsequently phosphorylated in sequential steps to 
tenofovir monophosphate and to the active metabolite, tenofovir di phosphate. In a mechanism 
similar to that of NRTIs, tenofovir di phosphate competes with its natural nucleotide counterpart, 
deoxy adenosine 5´-triphosphate, for incorporation into newly forming HIV DNA. Once 
successfully incorporated, termination of the elongating DNA chain ensues, and DNA synthesis 
is interrupted. Although the end result of tenofovir activity is similar to that of the NRTIs, subtle 
differences exist between this class of drugs and tenofovir. Like tenofovir, NRTIs also must be 
phosphorylated to active metabolites to inhibit reverse transcription of RNA into DNA. 
However, since tenofovir already contains a phosphate group attached to the adenine base, the 
initial addition of a phosphate group is circumvented; thus, only two steps are required in the 
phosphorylation of tenofovir, as opposed to three with the NRTI class. 
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4. AIM AND OBJECTIVE 
 
¾ Lamivudine is a nucleoside reverse transcriptase inhibitor. It can inhibit both types of 
HIV reverse transcriptase and also the reverse transcriptase of Hepatitis B. Tenofovir 
Disoproxil Fumarate is fumaric acid salt  of the bis isopropoxy carbonyl oxy methyl ester 
derivative of tenofovir. Nucleotide reverse transcriptase inhibitors used in combination 
for the treatment of HIV infection.  
¾ Literature survey reveals that Tenofovir Disoproxil fumerate and Lamivudine is 
estimated individually by UV, derivative – HPLC, Plasma RP-HPLC and Plasma 
LC/MS/MS methods. Few RP-HPLC methods were reported for estimation of 
Emtricitabine, Tenofovir and efavirenz in pharmaceutical formulation. 
¾ RP-HPLC, LC-MS/MS and HPTLC methods were reported for the simultaneous 
estimation of Emtricitabine and Tenofovir disoproxil fumerate in human plasma and in 
formulations.  Also UV, HPLC, LC–MS, HPTLC and enzymatic assay methods were 
reported for the simultaneous estimation of Lamivudine with other antiretero viral drugs. 
¾ To the best of our knowledge, there is no reported RP-HPLC method for Simultaneous 
Estimation of Lamivudine and Tenofovir disoproxil fumerate in pharmaceutical 
formulations, previous to our work.  
¾ Thus, efforts were made to develop fast, selective and sensitive analytical method for 
Simultaneous estimation of Lamivudine and Tenofovir disoproxil fumerate in their 
combined dosage form. 
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5. PLAN OF WORK 
                 
 
 
            Aimed to develop Simultaneous estimation method and validation for Lamivudine and 
Tenofovir in Pharmaceutical dosage form. 
 
The plan of the proposed work includes the following steps: 
• The extensive survey of literature for Lamivudine and Tenofovir regarding their physico-
chemical properties and analytical methods. This forms the basis for the development of 
methods.. 
• Selection of suitable solvent for quantitative extraction of analyte present in the 
formulations. The solvent should be readily available, economical and of analytical 
grade. 
• To develop initial chromatographic conditions by selection of suitable column and 
appropriate wavelength in UV for detection and optimization of the method. 
• To validate analytical method developed as per the ICH Q2B guidelines.  
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                                6. MATERIALS AND INSTRUMENTS 
 
  
 
 
 
6.1 Instruments:  
                                   Table No 3: Table showing list of the Instruments used 
 
S. No 
 
 
Name of the 
Instrument 
 
Make 
 
Model 
 
  1. 
 
 
       HPLC 
 
   Water 
 
   Alliance-2695 
  PDA Waters-2996 
 
 
2. 
 
 
Electronic balance 
 
Shimadzu 
 
  AY 220 
 
3. 
 
 
Digital pH meter 
 
Digisun Electronics 
 
   7007 
 
4. 
  
Centrifuge 
 
Thermolab 
 
  R8C 
 
5. 
  
PhotoStability 
Chamber 
 
 Thermolab 
 
943/03/0607 
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6.2 Reagents and chemicals: 
                                 Table No 4: Table showing list of the chemicals used 
 
S. No 
 
Name 
 
 
Grade 
 
 
Manufacturer/ 
Supplier 
 
    
   1. 
 
Lamivudine & Tenofovir working 
standard 
 
                - 
   
 
 
  2. 
 
         Acetonitrile 
 
 
           HPLC 
 
     Merck 
 
  3. 
     
  Potassium di hydrogen  
ortho phosphate 
 
 
          HPLC 
 
     Merck 
  
 4. 
       
       Methanol 
 
 
          HPLC 
 
     Merck 
  
 5. 
 
 
        Water 
 
             - 
 
         - 
 
 6. 
 
   
Milli Q Water 
 
        HPLC 
       
         - 
 
 
 
 
 
 
 
 
Chapter: 7                                                                                                 Experimental Part 
 
RVS College of Pharmaceutical Sciences, Coimbatore  Page 47 
 
                                        7.  EXPERIMENTAL PART   
 
7.1 METHOD DEVELOPMENT AND OPTIMIZATION OF LAMIVUDINE AND 
TENOFOVIR 
1. SELECTION OF DETECTOR WAVE LENGTH:  
The wave length selection is made at 260 nm since all the two compounds maximum 
absorbance in UV spectrum as reported in the literature is in 260 nm.  
2. OPTIMIZED CHROMATOGRAPHIC CONDITIONS: 
a. Selection of mode of separation: 
 As the drug was polar in nature, RP-HPLC method was preferred. 
Procedure: 
Preparation of TEA buffer: 
Dissolve 1ml of TEA (tri methyl amine) into a 250ml beaker with HPLC water. 
Adjusted the pH to 3.0 with ortho  phosphoric acid. 
Preparation of mobile phase: 
 Mix a mixture of above buffer 400mL (40%) and 600 mL of Methanol HPLC 
(60%) and degas in ultrasonic water bath for 5 minutes. Filter through 0.45 µ filter under 
vacuum filtration. 
Preparation of Standard Solution: 
                  Accurately 10 mg of Lamivudine & Tenofovir were weighed and transferred 
into 10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes 
to dissolve it. The volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipette out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was 
filtered through 0.45µm membrane filter. 
             Inject 20 μl of the standard solution into the chromatographic system and measure 
the area for the Lamivudine & Tenofovir peaks and calculate the %Assay by using the 
assay formula.  
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TRIAL&ERROR METHODS:  
TRIAL -1: 
CHROMATOGRAPHIC CONDITIONS: 
Column                    :  Symmetry C8 (4.6 x 150mm, 5 μm, Make: ACE) 
Detector                   : 260nm 
Flow rate                 :  0.6ml/min 
Injection volume     : 20µl 
Run time                 : 10min 
Mobile Phase          : Buffer (pH: 5.0):  Acetonitrile: Methanol (30: 40: 30) 
 
Results of Trial-1: Peak shape was not good, Due to asymmetry in peaks and longer 
RT’s another trial is made with change in mobile phase-buffer pH. 
 
TRIAL- 2: 
CHROMATOGRAPHIC CONDITIONS: 
Column                         : Symmetry C8 (4.6 x 150mm, 5 μm, Make: ACE) 
Detector                        : 260nm 
Flow rate                      : 0.7ml/min 
Injection volume          : 20µl 
Run time                      : 10min 
Mobile phase               : Buffer (pH-.4): methanol (50:50)  
Results of Trial-2: Peak shape was not good, Due to tailing in peaks and asymmetry, so 
reduce RT’s another trial is made with change in mobile phase-buffer pH and flow rate. 
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Trail-3:   
CHROMATOGRAPHIC CONDITIONS: 
Column                         : Symmetry C8 (4.6 x 150mm, 5 μm, Make: ACE) 
Detector                        : 260nm 
Flow rate                       : 0.8ml/min 
Injection volume            : 20µl 
Run time                        : 10min 
Column temperature      : 30°c 
 Mobile phase               : Buffer (pH-.3): methanol (60:40)  
Results of Trial-3(Final Optimized Method): Peak shape was good but second 
compound have more tailing factor so reduce RT’s another trail is made. The peaks are 
sharply resolved with less tailing and hence the trial-3 method is optimized for analysis. 
 
Final method: 
Column                         : Symmetry C8 (4.6 x 150mm, 5 μm, Make: ACE) 
Detector                        : 260nm 
Flow rate                       : 0.8ml/min 
Injection volume            : 20µl 
Run time                        : 10min 
Column temperature      :  30°c 
 Mobile phase               : Buffer (pH-.3): methanol (40:60)  
Results of Trial-4(Final Optimized Method): RT’s were observed at 2.448 
(Lamivudine), and 3.993 (Tenofovir). The peaks are sharply resolved with less tailing 
and hence the trial-4 method is optimized for analysis. 
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7.3 QUANTITATIVE DETERMINATION OF THE DRUG BY USING THE 
DEVELOPED METHOD 
Sample :  Lamivudine & Tenofovir 
Label claim : 300mg 
 
 Standard Solution Lamivudine & Tenofovir: 
                  Accurately 10 mg of Lamivudine & Tenofovir were weighed and transferred 
into 10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes 
to dissolve it. The volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipette out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was 
filtered through 0.45µm membrane filter. 
             Inject 20 μl of the standard solution into the chromatographic system and measure 
the area for the Lamivudine & Tenofovir peaks and calculate the %Assay by using the 
assay formula.  
 
 
 Sample Solution Lamivudine & Tenofovir:  
                          20 Lamivudine & Tenofovir tablets were weighed and the average weight 
was calculated. Accurately the sample equivalent to10 mg of Lamivudine & Tenofovir 
was weighed & transferred into 10ml volumetric flask about 7ml of diluent was added 
and sonicated for 5 minutes to dissolve it content. The volume was made up with mobile 
phase. The solution was filtered through 0.45µm membrane filter (stock solution). 
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              0.75ml of stock solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was 
filtered through 0.45µm membrane filter. 
 
Assay formula: 
                    AT               WS           DT                          
 --------------- x ----------x --------- x average weight of tablet 
           AS              DS           WT                   
Where,   
 AT = Peak Area of sample solution. 
 AS = Peak Area of standard solution. 
 WS = Weight of working standard taken in mg 
 WT = Weight of sample taken in mg  
 DS = Dilution of Standard solution  
 DT = Dilution of sample solution 
          
Acceptance criteria: The limit of assay is in between the 98% - 102% 
The chromatograms are as shown in Fig No: 2.5 & 2.6  and assay results are tabulated 
and are as shown in Table No: 6 
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Table  showing Assay Results of Lamivudine & Tenofovir: 
Table No: 6 
 
S. No Compound name Assay value 
1. Lamivudine 99.56% 
2. Tenofovir 99.1% 
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                                                 8. RESULTS AND DISCUSSION 
 
        8.1 VALIDATION  
Definition: Validation is a process of establishing documented evidence which provides a 
high degree of assurance that a specific process will consistently produce meeting, its 
predetermined specifications and quality attributes. 
The objective of the analytical procedure should be clearly understood since this will 
govern the validation characteristics which need to be evaluated. Typical validation 
characteristics which should be considered are listed below. 
• Accuracy  
• Precision  
• Specificity 
• Linearity & Range 
• Robustness 
• Ruggedness 
• System suitability testing  
 
After method development, the validation of the current method has been performed in 
accordance with USP requirements for assay determination (Category-I: analytical methods 
for quantitation of active ingredients in finished pharmaceutical products) which include 
accuracy, precision, selectivity, linearity and range, robustness and ruggedness. 
 
 
 
 
                                                                                                     Results and Discussion 
 
RVS College Pharmaceutical Sciences, Coimbatore  Page 57 
 
 
     8.2   SYSTEM SUITABILITY TESTING 
 
System suitability testing is an integral part of many analytical procedures. The tests 
are based on the concept that the equipment, electronics, analytical operations and samples to 
be analyzed constitute an integral system that can be evaluated as such. System suitability test 
parameters to be established for a particular procedure depend on the type of procedure being 
validated and the parameters like tailing factor, retention time, theoretical plates per unit, 
resolution factor are determined and the results are tabulated and are as shown in Table No: 7 
Method 
Preparation of Standard solution: 
Standard Solution Lamivudine & Tenofovir: 
                  Accurately 10 mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
             Inject 20 μl of the standard solution into the chromatographic system and measure the 
area for the Lamivudine & Tenofovir peaks and calculate the %Assay by using the assay 
formula.  
 Acceptance criteria: 
a. The column efficiency is not less than 2000 theoretical plates. 
b. The tailing factor for the analyte peak is not more then 2.0. 
c. The relative standard deviation for the replicate injections more than 2.0%.  
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Chromatograms showing system suitability testing of Standard Solutions of Lamivudine 
& Tenofovir. 
Fig No : 3.1 
 
Fig No : 3.2 
 
Fig No : 3.3 
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Fig No: 3.4 
 
Fig No : 3.5 
 
 
Table showing list of system suitability parameters of Lamivudine & Tenofovir. 
 
Table No : 7 
 
Parameters Lamivudine Tenofovir 
Tailing factor 1.1 1.3 
Retention time 2.445 3.974 
Theoretical plates per unit 2766.24 2853.19 
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    8.3  ACCURACY 
The accuracy of an analytical method is the closeness of that results obtained by that 
method to the true value. Accuracy may often be expressed as percent recovery by the assay 
of known added amount of analyte. 
Determination: 
The accuracy of the analytical method was determined by applying the method to the 
analyzed samples, to which known amounts of analyte had been added. The accuracy was 
calculated from the test results as the percentage of analyte recovered by the assay. 
Procedure: 
Preparation of Standard solution (75µg/ml):     
                  Accurately 10 mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
Preparation of 50% sample solution: 
                Accurately 5mg of Lamivudine & Tenofovir were weighed and transferred into 10ml 
volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to dissolve it. 
The volume was made up with mobile phase. The solution was filtered through 0.45µm 
membrane filter (Stock solution). 
     From this 0.75ml of solution was pipetted out and transferred into 10ml of volumetric 
flask and the volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter. 
Preparation of 100% solution: 
Accurately 10.0mg of Lamivudine & Tenofovir were weighed and transferred 10 ml 
volumetric flask, about 7ml of diluent and sonicated for 5 minutes to dissolve it. The volume 
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was made up with mobile phase. The solution was  filtered through 0.45µm membrane filter 
(Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
Preparation of 150% solution: 
                Accurately 15mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
                Inject 20μl of placebo and standard solutions of Accuracy -50%, Accuracy -100% and 
Accuracy -150% solutions into HPLC. Now calculate the amount obtained and amount added 
(API) for Lamivudine & Tenofovir  samples.  
Calculate the concentration in μg/ml in the spiked placebo in all the above cases by 
comparing with the standard solution. Calculate the individual recovery and mean recovery 
values. The chromatograms are as shown in Fig. No: 4.1, 4.2, 4.3 and the results are tabulated 
and shown in Table No: 8 
 
 
Formula:                                              (Amount recovered)   
                         %recovery     =                                                  × 100 
                                                           (Actual amount added) 
Acceptance criteria: 
Percentage recovery in all the cases should be between 98.0 and 102.0 %. 
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     8.4  PRECISION 
Precision of an analytical method is the degree of agreement among individual test 
results when the procedure is applied repeatedly to multiple sampling of a homogenous 
sample. Precision of analytical method is usually expressed as the standard deviation and 
relative standard deviation. 
Determination: 
The precision of the analytical method was determined by assaying sufficient number 
of samples and relative standard deviation was calculated. 
The precision of the instrument was determined by assaying the samples 
consecutively, number of time and relative standard deviation was calculated. 
Procedure: 
A) System Precision: 
Preparation of Standard Solution (75 µg/ml):  
                Accurately 10mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
Inject 20µl of the blank solution and the standard solution of for six times and calculate the 
%RSD for the area of six replicate injections.The chromatograms are as shown in Fig No: 5.2-5.7  
and the results are tabulated shown in Table No:9. 
Blank solution: Mixture of phosphate buffer (pH3) & methanol  in ratio of 40:60 was filtered 
and degassed. 
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8.5 SPECIFICITY: 
             Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically these might include impurities, 
degradants, matrix, etc. 
 
Procedure: 
Preparation of placebo :  
 Placebo was prepared by mixing all the excipients without active ingredients. 
                 Accurately 28.34mg of placebo was weighed and transferred into 10ml volumetric 
flask, about 7ml of diluent was added and sonicated for 5 minutes to dissolve it. The volume 
was made up with mobile phase. The solution was filtered through 0.45µm membrane filter 
(Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
        Inject 20 µl of Standard solution for six times into the HPLC system and chromatograph. 
Compare the chromatograms visually and check for any interference. 
 
 
Preparation of Standard solution (75µg/ml):  
                 Accurately 10mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
        Inject 20 µl of Standard solution for six times into the HPLC system and chromatograph. 
Compare the chromatograms visually and check for any interference. 
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Preparation of Standard + placebo:  
                 Accurately 10mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluents was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipette out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
        Inject 20 µl of Standard solution for six times into the HPLC system and chromatograph. 
Compare the chromatograms visually and check for any interference. The solution was 
filtered through 0.45m membrane filter. The solution was injected and the reports are given in 
table: 10 
    
    %RSD Formula:  (σ /µ)*100 
Acceptance criteria: 
 There should not be any peak in the blank and Placebo solution run at the retention time 
corresponding to Lamivudine & Tenofovir as in standard run. 
 
Chromatogram showing Specificity- Blank solution  
Fig No : 6.1 
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 Table showing results of Specificity of Lamivudine & Tenofovir. 
Table No : 10  
 
 
 
 
 
 
 
8.6 LINEARITY&RANGE 
  
LINEARITY:  Linearity is the ability of the method to obtain test results that are directly 
proportional to the analyte concentration within a given range. 
 Range: Range of analytical procedure is the interval between the upper and lower 
concentration of analyte in the sample (including concentrations) for which it has been 
demonstrated that the analytical procedure has a sutable level of precision, accuracy, and 
linearity. 
Procedure:  
Preparation of Standard Stock Solution:  
                 Accurately 10mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
Preparation of (25, 50, 75, 100 and 125  µg/ml) sample solutions:  
 From the above stock solution pipette out 0.25, 0.5, 0.75, 1.0 and1.25ml respectively 
into individual 10ml of volumetric flasks and diluted up to the mark with diluent to prepare 
25,50,75,100,125,150 µg/ml of sample solutions respectively. Mix well and filter through 
0.45µm filter.       
 Inject 20µl of blank solution and each linearity level standard solutions into the 
chromatographic system and measure the peak area. Plot a graph of peak area versus 
Parameter Lamivudine Tenofovir 
Average area 6736932.6 4473768.2 
SD 78415 48869 
%RSD 1.16 1.09 
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concentration (on X-axis concentration and on Y-axis Peak area) and calculate the correlation 
coefficient. The results are tabulated shown in Table No: 11 
                          
 
   Acceptance criteria for Range: 
¾ Correlation coefficient should not be less than 0.99% 
 The linearity data and analytical performance parameters of are shown in table and calibration 
curve of is shown Fig No: 7.6,7.7.  
 
Chromatogram  showing Linearity level-1 (25µg/ml) Lamivudine & Tenofovir. 
Fig No : 7.1 
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Chromatogram showing Linearity level-2 (50µg/ml) of Lamivudine & Tenofovir.  
Fig No: 7.2 
 
 
Chromatogram showing Linearity level-3 (75µg/ml) of Lamivudine & Tenofovir. 
Fig No : 7.3 
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Chromatogram showing Linearity level-4 (100µg/ml) of Lamivudine & Tenofovir. 
Fig No : 7.4 
  
 
 
 Chromatogram showing Linearity level-5 (125g/mlµ) of Lamivudine & Tenofovir. 
Fig No : 7.5 
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 Linearity Results (for Lamivudine): 
Table No : 11 
S. No Linearity Level Concentration Area 
1 I 25µg/ml 2266976 
2 II 50µg/ml 4954694 
3 III 75µg/ml 6730592 
4 IV 100µg/ml 
8384491 
5 V 125µg/ml 10209389 
Correlation Coefficient 0.999 
 
 
Figure showing Linearity graph of Lamivudine. 
Fig No : 7.6 
 
 
 
 The correlation coefficient value was found to be 0.999 
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Linearity Results for Tenofovir: 
Table No : 12 
S. No Linearity Level Concentration Area 
1 I 25µg/ml 1529418 
2 II 50µg/ml 2898127 
3 III 75µg/ml 4568836 
4 IV 100µg/ml 
5693545 
5 V 125µg/ml 6999247 
Correlation Coefficient 0.9996 
 
 
 Figure showing linearity graph of Tenofovir. 
Fig No : 7.7 
 
 
The correlation coefficient value was found to be 0.9996 
y = 55839x + 74910
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8.7 ROBUSTNESS 
 
  It is a measure of ability to remain unaffected by small but deliberate variations in method 
parameters and provides an indication of its reliability during normal usage. 
          The robustness of an analytical method was determined by analysis of aliquots from 
homogenous lots by differing physical parameters that may differ but were still within the 
specified parameters of the assay for example change in physical parameters like flow rate, 
column temperature and mobile phase ratio. 
A ) the flow rate was varied at 0.7 to 0.9 ml/min. 
Preparation of Standard Solution (75µg/ml):  
                Accurately 10mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
         Inject 20µl of the blank solution and the standard solution of 75 µg/ml for five times 
and analysed using varied flow rates (0.7ml, 0.9 ml) along with method flow rate and 
calculate the %RSD for the area of five replicate injections.  
 
a) The flow rate was varied at ±0.1 ml/min. 
%RSD of Lamivudine & Tenofovir assay under these conditions is calculated and the results 
are shown in below. 
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PROCEDURE 
a) The flow rate was varied at ±0.1 ml/min.  
  Standard solution 70 µg/ml was prepared and analysed using the varied flow rates 
along with method flow rate and the chromatograms were recorded. The results are 
shown in table 11. 
 
Flow variation-1 (0.7mL/min): 
 Chromatogram showing Robustness-Flow variation (0.7ml/min) of Lamivudine & 
Tenofovir. 
Fig No  : 8.1 
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Robustness flow rate (0.9ml): 
Fig No :8.2 
 
B)  Mobile phase 
 
Preparation of Standard Solution (75µg/ml): 
                   Accurately 10mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution).From this 0.75ml of solution was pipetted out and 
transferred into 10ml of volumetric flask and the volume was made up with mobile phase. 
The solution was filtered through 0.45µm membrane filter. 
   Inject 20µl of the blank solution and the standard solution of 75 µg/ml for five times 
and analysed using the varied Mobile phase composition along with the actual mobile phase 
composition in the method and calculate the %RSD for the area of five replicate injections. The 
chromatograms are as shown in Fig No: 40 and the results are tabulated shown in Table No: 16. 
    %RSD Formula:  (σ /µ)*100 
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    Acceptance criteria: 
Relative standard deviation (RSD) of areas of Lamivudine & Tenofovir from five standard 
chromatograms in all the flow rate variation and mobile phase composition should not be more 
than 2.0 %. 
 
 The Organic composition in the Mobile phase was varied from ±5%: 
          Standard solution 70 µg/ml was prepared and analysed using the varied Mobile phase 
composition along with the actual mobile phase composition in the method and the 
chromatograms were recorded.  
The graphs are shown in fig 8.3and 8.4  and the results are shown in table no : 13 . 
 
ROBUSTNESS MOBILE PHASE (35:65) 
Fig No :8.3 
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ROBUSTNESS MOBILE PHASE (45:55) 
Fig No: 8.4 
 
Table showing Robustness results for change in flow rate and mobile phase of 
Lamivudine & Tenofovir. 
Table No : 13 
Flow rate Inj. Sample Area  Plate count Tailing RT 
 
0.7ml/min 
Lamivudine 8344338 2671.86 1.1 2.79 
Tenofovir 5675524 2876.79 1.4 4.54 
 
0.9ml/min 
Lamivudine 6590717 2575.82 1.1 2.58 
Tenofovir 4500085 2800.83 1.5 3.54 
Mobile phase 
variation 
 
 
35:65 
Lamivudine 6329717 2652.12 1.2 2.44 
Tenofovir 3990067 2795.62 1.4 3.97 
 
45:55 
Lamivudine 7408362 2580.74 1.0 2.44 
Tenofovir 5077859 2785.37 1.4 3.34 
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8.8 RUGGEDNESS 
 
              Ruggedness as the degree of reproducibility of test result obtained by the analysis of 
the same of the samples under verity of normal test conditions, such as different labs, 
different analyst, and different lots of reagents, different elapsed assay times, different assay 
temperature, different days etc. 
                Ruggedness is normally expressed as the of influence on test results of operational 
and environmental variables of the analytical method. 
 
Procedure: 
Preparation of Standard Solution (75µg/ml):  
                Accurately 10mg of Lamivudine & Tenofovir were weighed and transferred into 
10ml volumetric flask, about 7ml of diluent was added and sonicated for 5 minutes to 
dissolve it. The volume was made up with mobile phase. The solution was filtered through 
0.45µm membrane filter (Stock solution). 
                 From this 0.75ml of solution was pipetted out and transferred into 10ml of 
volumetric flask and the volume was made up with mobile phase. The solution was filtered 
through 0.45µm membrane filter. 
                  Inject the blank solution and standard solution of 75µg/ml for six times and analysed 
by two analysts and calculate the %RSD for the area of  injections. 
Ruggedness of the current method was demonstrated by analyzing two samples 
(assay) of tablet formulation by two analysts in the same laboratory on two different days. 
The chromatograms are as shown in Fig.No:9.1-9.4 and the results are as shown in the Table 
No:14 and15  indicating the ruggedness of the method. 
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Chromatogram showing Ruggedness: Day-1, Analyst-1 of Lamivudine & Tenofovir 
Fig No : 9.1  
        
      
 
Fig No : 9.2 
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Chromatogram showing Ruggedness: Day-2, Analyst-2 of Lamivudine & Tenofovir. 
Fig No : 9.3 
          
                
 
Fig No :9.4 
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 Chromatogram showing Ruggedness: different columns, instruments, analyst of 
Lamivudine & Tenofovir 
Table No : 14 
 
  S.No 
 
Column 
Code 
 
Instrument 
Code 
 
Analyst 
 
Result 
Obtained (%) 
Lamivudine Tenofovir 
 
 
1. 
 
C-01 
 
W-29 
 
I 
 
99.5% 
 
99.25 
 
2. 
 
C-02 
 
W-30 
 
II 
 
99.85% 
 
99 
 
Table No : 15 
 
       
Parameter 
    
Result observed 
       
Acceptance Criteria 
Lamivudine Tenofovir 
 
 
Percentage Content 
 
 
99.67 
 
99.12 
 
98 – 102% 
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    9.1 SUMMARY 
 
 
Method development: 
 The developed method has an advantage of Lamivudine & Tenofovir in RP-HPLC. 
The following tables give the results of the method development quantitation  and validation 
parameters. 
 
FIXED CHROMATOGRAPHIC CONDITION 
Table No: 16 
 
 
OPTIMIZED CHROMATOGRAPHIC CONDITIONS 
Mode of separation isocratic elution 
Mobile phase Solvent-A: Phosphate buffer pH-3 
Solvent-B: methanol 
Column Symmetry C8 (4.6 x 150mm, 5 μm, 
Make: ACE) 
Flow rate 0.8 mL/ min 
Detection  Wavelength 260 nm 
Injection volume 20 μl 
Column oven temperature Ambient(30°C) 
Run time 10 min 
 
 
Quantitative Estimation 
 
Table No: 17 
 
 
S. No Compound name Assay value 
1. Lamivudine 99.56% 
2. Tenofovir 99.1% 
 
Acceptance criteria: 98-102% 
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Table showing Summary of results of method validation for Lamivudine & Tenofovir 
Table no:  18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
S. No Parameter Requirement results Acceptance criteria 
   Lamivudine Tenofovir  
1. 
System 
suitability 
RT 2.445 3.99  
2. 
Tailing factor 1.1 1.3 NMT 2 
3. 
4. Plate count     2766.24 2853.19 NLT 2000 
5.  Assay value 99.56% 99.1 98-102% 
6. Accuracy % Recovery 98.965 98.84% 98-102% 
7. Precision %RSD 1.20 1.74 NMT 2% 
8. Specificity  No interference  
Pass pass No interference 
8. Linearity Correlation coefficient 0.999 0.999 NLT 0.999 
9. Range Concentration 25-125µg/ml 
25-
125µg/ml Nil 
10. Robustness %RSD 1.37 1.56 NMT 2% 
11. Ruggedness %RSD 99.67 99.12 98-102% 
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                 9.2 CONCLUSION 
 
¾ A new method is developed for Simultaneous Estimation of  Lamivudine and 
Tenofovir by RP-HPLC method. The sample preparation is simple and the 
analysis time is short. The analytical procedure is validated as per ICH Q2B 
guidelines and shown to be accurate, precise and specific.  
 
¾ This method represents a fast analytical procedure for the simultaneous 
quantization of Lamivudine and Tenofovir. The method is amenable to the 
routine analysis of large numbers of samples with good precision and 
accuracy. 
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